KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Shares Issued (2016 - 2025)

Acadia Pharmaceuticals (ACAD) has 16 years of Shares Issued data on record, last reported at $22.7 million in Q4 2025.

  • For Q4 2025, Shares Issued rose 1051.14% year-over-year to $22.7 million; the TTM value through Dec 2025 reached $49.9 million, up 628.75%, while the annual FY2025 figure was $49.9 million, 628.75% up from the prior year.
  • Shares Issued reached $22.7 million in Q4 2025 per ACAD's latest filing, up from $9.4 million in the prior quarter.
  • Across five years, Shares Issued topped out at $22.7 million in Q4 2025 and bottomed at $268000.0 in Q3 2024.
  • Average Shares Issued over 5 years is $5.4 million, with a median of $3.7 million recorded in 2022.
  • Peak YoY movement for Shares Issued: surged 4342.86% in 2023, then plummeted 97.9% in 2024.
  • A 5-year view of Shares Issued shows it stood at $4.4 million in 2021, then crashed by 63.02% to $1.6 million in 2022, then surged by 236.68% to $5.4 million in 2023, then tumbled by 63.77% to $2.0 million in 2024, then soared by 1051.14% to $22.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Issued were $22.7 million in Q4 2025, $9.4 million in Q3 2025, and $16.0 million in Q2 2025.